source
- Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionAs the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.Fierce Biotech · 6h ago↗ source
- Climate change worsens symptoms for people with chronic illnesses, author reports from Chicago smoke eventsThe author argues that climate change is already harming health, particularly for those living with chronic conditions, and that the impact is becoming more evident. She describes a recent summer…
- Postpartum psychiatry remains inadequately understood, case of Lindsay Clancy highlights gaps